Today’s updated prescription data from Symphony Health Solutions suggests a declining market share for Zubsolv in the US in December, amounting to 4.3% in quantity (4.5% in October). Weekly volumes (rolling 4-week average) remains above 350,000, more or less unchanged compared to the levels seen in October.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se